Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03193151 · ClinicalTrials.gov registry record

Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation

A clinical trial of Liver Dysfunction, sponsored by University of Alberta.

Recruiting
Registry status
300
Enrollment target
15
Study locations

NCT03193151 is a study of Liver Dysfunction that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 300 participants. The trial reports 15 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03193151, a study of Liver Dysfunction, is actively recruiting participants, sponsored by University of Alberta.

RECRUITING
Registry status
300 participants
Enrollment target
15
Study locations

Study Summary

INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.

Conditions Studied

Interventions

  • PROCEDURE liver biopsy

Study Locations (15)

Other

  • Centenary Institute of Cancer Medicine & Cell Biology, Royal Prince Alfred Hospital - Camperdown
  • Dep. of Nephrology, Transplantation & Internal Med., Samodzielny Publiczny Szpital Kliniczny im. A. Mieleckiego - Katowice
  • Independent Public Composite Regional Hospital - Szczecin
  • Warsaw Medical University, Jesus the Child Clinical Hospital - Warsaw
  • Warsaw Medical University, Independent Public Clinical Hospital - Warsaw
  • Institute for Liver Science, King's College London - London

California

  • University of California San Francisco, Transplant Research Unit - San Francisco

Illinois

  • Northwestern Memorial Hospital - Chicago

Maryland

  • University of Maryland School of Medicine - Baltimore

Michigan

  • Henry Ford Transplant Institute - Detroit

Tennessee

  • Vanderbilt University Medical Center, Vanderbilt Transplant Center - Nashville

Texas

  • Baylor University Medical Center, Annette C. and Harold C. Simmons Transplant Institute - Dallas

Virginia

  • Transplant Surgery, VCU Medical Center - Richmond

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2017-12-19
Est. Completion 2027-12

Sponsor

University of Alberta

19 total trials

What the Registry Record Tells You About NCT03193151

The ClinicalTrials.gov registry entry for NCT03193151 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alberta, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which liver biopsy is the first listed.

NCT03193151 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT03193151 about?

NCT03193151 is a clinical study titled "Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation". INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used...

What is the current status of trial NCT03193151?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2017-12-19. Estimated completion is 2027-12.

What conditions does trial NCT03193151 study?

This clinical trial studies the following conditions: Liver Dysfunction.

What interventions are being tested in trial NCT03193151?

The interventions under investigation include: liver biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT03193151?

This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03193151 being conducted?

This trial has 15 study locations across California, Illinois, Maryland, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.